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Abstract
Background
Locally advanced esophageal carcinoma (LAEC) represents less than 30% of all diagnosed
esophageal carcinoma worldwide. The standard of care for resectable tumours consists of
preoperative chemoradiotherapy (CRT) followed by surgery. Despite the curative intent, the
prognosis is still poor mainly due to relapse. A multidisciplinary approach is required in order
to optimize the therapeutic strategy and follow-up. Differences in outcomes between the two
main histological subtypes, adenocarcinoma (ADC) and squamous cell carcinoma (SCC),
have been reported. Nevertheless, the heterogeneity in trials design and data available
have hampered the achievement of clear conclusions. The purpose of this study is to report
the outcomes from a cohort of patients with LAEC treated with a multidisciplinary approach
and to remark the differences observed between the two main histologic subtypes and their
clinical implications.
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Methods
We retrospectively reviewed 100 patients diagnosed with LAEC that were treated with pre-
operative CRT at our institution and integrated centres. Histopathological characteristics
and toxicities during treatment were recorded. Patterns of recurrence at the first relapse
were analysed. Survival curves were plotted using the Kaplan Meier method and multivari-
ate Cox proportional hazards models were used.
Results
Among the patients who received preoperative CRT, 83% underwent surgery. The median
overall survival (mOS) was 31.7 months, 26.9 months for ADC and 45.5 for SCC (p-value =
0.33). In the multivariate Cox regression analysis, ypN+ was the only factor that negatively
influenced in OS (OR = 4.1, p-value = 0.022). Patterns of recurrence differed according to
histologic subtype. Distant relapse was more frequent in ADC (62%), whereas locoregional
relapse was higher in SCC (50%) (p-value = 0.027). Second line therapeutic strategies
could be offered to 50% of those patients who relapsed.
Conclusions
Differences in outcomes and recurrence pattern could be observed between the two main
histologic subtypes of LAEC. A better molecular characterization, adapted therapeutic regi-
mens and follow up strategies should be adopted in order to improve survival of these
patients.
Introduction
The incidence of esophageal carcinoma in Europe is around 4.5 cases/100.000 habitants per
year, causing more than 400,000 deaths annually [1]. The aggressive behaviour of the disease
confers a poor prognosis, with a five-year overall survival (OS) that rarely exceeds 40% in
locally advanced tumours, and less than 5% in metastatic disease [2].
Over the last few decades, esophageal carcinoma incidence and mortality have varied sub-
stantially across the world, with important differences between the two main histological sub-
types, squamous cell carcinoma (SCC) and adenocarcinoma (ADC). Although SCC accounts
for about 90% of cases worldwide, it has declined substantially in some regions the last few
years, whereas the incidence of ADC has progressively increased. Because the pathogenesis of
both subtypes is different, the distribution pattern is changing and varies across the regions
depending mostly on the life-style habits. Alcohol and tobacco consumption are associated
with SCC whereas the main risk factors for ADC are high fat diet, obesity and gastroesophageal
reflux disease (GERD) [3–5].
Locally advanced esophageal carcinoma (LAEC) comprises those tumours that invade
through the muscular layer and involve other adjacent structures or lymph nodes (T3-4N0
and T1-4aN1, M0) [6]. It represents a potentially curable disease but prognosis is limited
mainly due to relapse [7]. Several clinical trials attempted to determine whether the preopera-
tive CRT is superior to other therapeutic approaches in this setting. Different staging tech-
niques, and heterogeneous trial designs and data, are some of the reasons that explain the lack
of strong evidence about which strategy we might follow. Recently, a number of single-
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institution trials have been performed demonstrating the benefit of concurrent chemora-
diotherapy (CRT) followed by surgery in LAEC. It achieves higher rates of complete tumour
resection (R0) without increasing surgical mortality, better locoregional tumour response
(ypTN), and micrometastatic disease control that enhances better survival [8–11]. Despite the
differences observed in response rate and prognosis according to histologic subtype, there are
no consistent data to support that histology is a predictive biomarker of CRT in esophageal
carcinoma [12].
The main purpose of this retrospective study is to report the outcomes and prognosis in a
cohort of patients with LAEC treated with concurrent CRT followed by surgery, in a mono-
graphic oncologic institution, and to describe patterns of recurrence, assessing the influence of
histologic subtypes.
Methods
Study population
This study was approved by the Institutional Review Board and Ethics Committee from Hospi-
tal Universitari de Bellvitge, and recorded data was anonymized for analysis. In this retrospec-
tive study, we reviewed 100 consecutive patients diagnosed with LAEC treated at the Catalan
Institute of Oncology (ICO), Bellvitge University Hospital (HUB) and integrated centres
between 2005 and 2014. Eligible patients for this study had histological or cytological confir-
mation of esophageal carcinoma. Staging assessment confirmed locally advanced disease (T3-
4N0 and T1-4aN1, M0). Carcinomas of the esophago-gastric junction (EGJ) Siewert 1 and Sie-
wert 2 (Siewert 2, only until 2012), were also included. All patients were reviewed in the gas-
tro-esophageal multidisciplinary tumour board, a multidisciplinary committee composed by
different healthcare professionals that comprises radiologists, surgeons, oncologists, gastroen-
terologists, pathologists, nutritionists, and specialised nurses. Those patients considered candi-
date to receive concurrent CRT followed by surgery were included in the study.
The staging assessment included gastric fibroscopy, endoscopic ultrasonography (EUS)
when confirmation of locoregional lymph nodes involvement was needed, and a bronchos-
copy in all supracarinal tumours or in case of airway infiltration suspicion. A baseline positron
emission tomography scan (PET CT) was performed in all cases to exclude distant metastasis.
The final stage was established according to the International Union against Cancer (UICC)
and tumour—node—metastasis (TNM) classification (AJCC/UICC 7th Edition) [6].
Therapeutic approach and follow-up
Patients were candidates to receive preoperative chemoradiotherapy (CRT) with of Cisplatin
(80 mg/m2/d) and infusional 5-Fluoracil (1000 mg/m2/d) doublet on days 1 to 4. Carboplatin
was used in case of renal function impairment, hearing loss, or elderly. Intensity-modulated
radiotherapy dose of 45 or 50,4 Gy in 1,8 Grays/fraction was administered depending on the
centre protocol.
The overall response rate was evaluated by PET CT four weeks after completing RT. In case
of tumour response or stable disease, surgery was offered to all fit patients with operable
tumours.
Surgical techniques were performed depending on tumour location and surgical risk was
assessed for every patient. McKeown for supracarinal tumours (transthoracic esophaguectomy
plus neck gastroplasty), Ivor-Lewis for infracarinal tumours (esophaguectomy plus intratho-
racic gastroplasty) or transhiatal esofaguectomy in case of frail patients or comorbidities.
All G3-4 toxicities during the CRT treatment, as well as postoperative mortality within the
first 30 days, were recorded.
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The pathology report described histologic subtype, grade of differentiation, vascular, peri-
neural and lymphatic invasion, surgical margins and tumoral regression assessment according
to Mandard classification [13,14]. A microscopic margin of less than 1 mm was considered as
positive, and proximal and distal macroscopic margins of at least 2 cm beyond gross tumour
were required for considering negative surgical margins. The ypTNM (AJCC/UICC 7th Edi-
tion, 2010) was evaluated in order to know the downstaging after preoperative CRT.
Follow-up controls were conducted regularly after therapy. A thoracic—abdominal CT
scan was performed annually since the date of surgery, until 5 years follow-up. Pattern of
recurrence: locoregional, distant, or synchronic locoregional and distant were recorded for the
two main histologic subtypes (ADC and SCC).
Statistics
Data was collected retrospectively. Chi-square test (X2) was used for categorical variables com-
parison. Median follow-up was calculated from the starting treatment date until the last fol-
low-up for surviving patients. Kaplan—Meier method was used to plot overall survival (OS)
and progression free survival (PFS) and log-rank test was used to estimate statistical differ-
ences, with 95% confidence intervals (CI). Univariate and multivariate analyses were per-
formed by the Cox proportional hazard regression model to assess the prognostic value of
different histopathological variables. A multiple regression analysis for recurrence was also
performed. Two-tailed p-value less than 0.05 was established to assume significant differences.
All analyses were carried out using the SPSS v.21.0 (IBM Corp., Armonk, NY, USA).
Results
Characteristics of patients
Between 2005 and 2014, 100 patients were included in the study. Clinico-pathological charac-
teristics and treatment received are summarized in Table 1. Median age was 61 years old
(range 34–78). Most of them were male (93%) and current or former smokers (77%). Most fre-
quent histology was ADC (53%), followed by SCC (43%). 82% of tumours were located in
esophagus whereas 18% in the EGJ. 91% of patients presented cT3-4 and 88% had nodal
involvement (cN+) at diagnosis.
All patients received preoperative concurrent CRT. The median cycles of CT were 2. Cis-
platin-5-Fluoracil was the most used regimen (83%) and it was well balanced between the two
main histologic subtypes (86% of SCC, and 81% of ADC). 76% of patients received 45 Gy of
RT dose, whereas 18% of patients, 50.4Gy, depending on the centre protocol. Treatment char-
acteristics in the all cohort (N = 100) and according to the two main histologic subtypes (SCC,
N = 43 and ADC, N = 53) is indicated in Table 2. The overall response rate was 19% complete
response (CR), and 55% partial response (PR). 83% of patients were able to undergo radical
surgery. Grade 3/4 toxicity events during preoperative CRT occurred in 18% of patients,
mostly due to G3 neutropenia (5% of patients), G3 mucositis (4%), G3 esophagitis (4%), fol-
lowed by G3 emesis (3%) and G3 febrile neutropenia (2%). Deaths due to post-operative com-
plications (within 30 days) occurred in 2 patients (2.4%).
Pathological assessment and outcomes
Among 83 resected tumours, 54% were ADC and 42% SCC. 87% had negative margins (R0).
Pathologic complete response (ypCR) was achieved in 24% of the patients (18% of resected
ADC (n = 8) and 34% SCC (n = 12), p = 0.12). Lymph node downstaging rate, from positive to
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Table 1. Characteristics of patients.
All Patients
N = 100 (100%)
Age—years (range)
Median 61 (34–78)
Sex—n˚ (%)
Male 93 (93)
Female 7 (7)
Tobacco habit—n˚ (%)
Never 14 (14)
Former 38 (38)
Current 39 (39)
Unknown 9 (9)
Alcohol habit—n˚ (%) 43 (43)
Never 21 (21)
Former 27 (27)
Current 9 (9)
Unknown
Performance Status—n˚ (%)
PS0 3 (3)
PS1 86 (86)
PS2 3 (3)
Unknown 8 (8)
Barrett Esophaegus—n˚ (%)
Yes 18 (18)
No 82 (82)
Histology—n(%)
Adenocarcinoma 53 (53)
Squamous Cell Carcinoma 43 (43)
Undifferentiated 2 (2)
Not determined 2 (2)
Location—n˚ (%)
Esophagus
Upper 7 (7)
Middle 35 (35)
Lower 40 (40)
OGJ—Siewert
Siewert 1 13 (13)
Siewert 2 5(5)
cT—n˚ (%)
Tx 1 (1)
T2 8 (8)
T3 70 (70)
T4a 19 (19)
T4b 2 (2)
cN—n˚ (%)
Nx 2 (2)
N0 10 (10)
N+ 88 (88)
https://doi.org/10.1371/journal.pone.0184737.t001
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negative nodes was 61% (44/72 patients). Tumour pathologic response using Mandard regres-
sion score was also recorded. Histopathologic results are summarized in Table 3.
At the time of the analysis, median follow-up for surviving patients was 38.4 months (range
8–118). Recurrence rate (RR) at 1st and 3r year were 36% and 43%, respectively.
Median disease-free survival (DFS) was not reached for SCC subgroup, whereas for ADC
was 16.5 months (p<0.24).
Median OS was longer for SCC 45.4 m than for ADC 32 m, despite no significant differ-
ences were found (p-value = 0.33). Overall survival rates at 1st and 3rd year were 66,3% and
53%, respectively (Fig 1).
In the multivariate analysis of OS adjusted by age, sex, histology, ypCR, and response to
NA CRT, ypN+ was an independent prognostic factor for OS (HR = 2.24, 95% CI 1.14–4.38;
p-value = 0.019). In the multiple logistic regression analysis for recurrence risk, ypN+ remained
as a predictive factor for recurrence (OR = 4.4; 95% CI 1.6–13.1; p-value = 0.022) (Table 4).
Pattern of recurrence
The overall recurrence rate (RR) of patients who underwent surgery was 43% (36 patients):
34% of resected SCC (n = 12), and 47% of resected ADC (n = 21). Among all of them, 55% had
distant recurrence, being ADC the most frequent histology (72%); 12% had exclusively locore-
gional relapse, being 75% SCC; the remaining 33% had synchronic locoregional and distant
recurrence, p-value = 0.027 (Table 5).
Among the patients who relapsed (n = 36), 50% were candidates to receive further treat-
ment. Two patients presented a single metastatic site at progression after surgery. Both were
treated with curative intention. The first one, who had a SCC, underwent salvage surgery for
Table 2. Treatment received by all cohort of patients and according to main histologic subtypes (SCC and ADC).
Treatment All Patients
N = 100 (100%)
SCC
N = 43 (100%)
ADC
N = 53 (100%)
NA CT—n˚ (%) 83 (83%)
CDDP-5FU 9 (9) 37 (86%) 43 (81%)
CBDCA-5FU 2 (2) 1 (2) 8 (15)
CBDCA-Taxol 3 (3) 1(2) 1 (2)
Other 3 (3) 2(5) 0 (0)
Unknown 2 (5) 1 (2)
N˚ of cycles (CT)
Median (range) 2 (1–4) 2 (1–4) 2 (1–3)
RT (Gy)—n˚ (%)
45 76 (76%) 31 (72%) 41 (79%)
50,4 18 (18) 10 (23) 8 (15)
Other 6 (6) 2 (2) 4 (6)
Median dose (Gy) 45 (40–65) 45 (45–63) 45 (40–65)
Surgery—n˚ (%)
Yes 83 (83%) 35 (81%) 45 (85%)
No 17 (17) 8 (19) 8 (15)
Reason for no surgery—n˚ (%) N = 17 N = 8 N = 8
Unresectable 11 (64,7%) 5 (63%) 6 (75%)
Patient denial 2 (11,8) 1 (12) 1 (12.5)
Other 4 (23,5) 2 (25) 1 (12.5)
NA, Neo-adjuvant; CDDP, Cisplatin; CBDCA, Carboplatin; 5FU, 5-Fluoracil; CT, chemotherapy; RT, radiotherapy.
https://doi.org/10.1371/journal.pone.0184737.t002
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the metastasis in the brain. Unfortunately, he died due to post-surgical complications. The
other one, diagnosed with ADC, received concurrent CRT (for locoregional lymph nodes
relapse) and the survival after relapse improved by 16 months. The rest of patients (86%) were
eligible for palliative chemotherapy (n = 15) and palliative external RT (n = 1) (Table 6).
Among this group of patients, 90% had performance status1. Median time on treatment
was 2.1 months (range <1-5m) and 38% of patients received subsequent lines of chemother-
apy. Median OS from recurrence date was 3 months (CI 95% 0.5–5.6). 6.5m (4.4–8.5) for
patients who received any treatment at recurrence compared with 1.6m (1–2.3) for those who
received best supportive care (p-value = 0.026).
Discussion
The two main histologic subtypes of esophageal carcinoma are SCC and ADC. They represent
two distinct diseases with different epidemiology and prognosis. Preoperative treatment in
both histologies is clearly indicated in operable patients. In a recent clinical trial (CROSS trial,
NTR487), preoperative chemo-radiotherapy showed significantly higher response rate in SCC
compared to ADC, but no significant differences in OS could be demonstrated [15].
The multidisciplinary approach delivered to our patients lead to an optimal individual stag-
ing which determined preoperative decision making. Nowadays, several clinical guidelines rec-
ommend the involvement of multidisciplinary teams in the management of oncologic patients
due to the benefits evidenced on outcomes [16]. One of the goals successfully achieved by our
multidisciplinary tumour board has been to standardize and optimize therapeutic strategies
for all patients with positive benefit on outcomes over the last few years [17,18].
Table 3. Pathologic results from patients with resection (surgery).
Pathologic Results All patients with resection
N = 83
Histology—n˚ (%)
Adenocarcinoma 45 (54%)
Squamous cell carcinoma 35 (42)
Undifferentiated 2 (3)
Unknown 1 (1)
Margins—n˚(%)
R0 72 (87%)
R1 6 (7)
Unknown 5 (6)
Downstaging T3/4 (n = 77) to Tx/1/2—n˚ (%)
Yes 44 (57%)
No 33(43)
Downstaging cN+ (n = 72) to ypN0—n˚ (%)
Yes 44 (61)
No 28 (39)
SCC ADC P- value
ypCR—n˚ (%) N = 80 N = 35 N = 45
Yes 20 (24%) 12 (34%) 8 (18%) 0.12
No 60 (76%) 23 (66%) 37 (82%)
ypCR, pathologic complete response.
https://doi.org/10.1371/journal.pone.0184737.t003
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Our cohort comprised 21 patients (21%) with T4 staging at diagnosis and 88% cN+, confer-
ring a more aggressive disease according to the TNM classification 7th Edition AJCC [6].
Among the patients who underwent surgery after concurrent CRT (83%), ypCR was achieved
in 24% of cases, with a higher proportion of SCC subtype. cN+ downstaging was achieved in
61% of patients, thus ypN+ resulted as an independent prognostic factor for recurrence disease
Fig 1. Overall survival (OS) according to histologic subtype.
https://doi.org/10.1371/journal.pone.0184737.g001
Table 4. Multiple logistic regression analysis for recurrence in all patients with resection (n = 83).
Variable OR (CI 95%) P- value
Gender (male vs female) 0.00 0.99
Age (<60y vs > 60 years) 0.9 (0.3–2.8) 0.87
Histology: ADC vs SCC 0.7 (0.24–2.12) 0.5
cN (cN0 vs cN+) 2.5 (0.24–26.5) 0.43
ypCR (non ypCR vs ypCR) 1.8 (0.42–7.6) 0.43
ypN (ypN0 vs ypN+) 4.1 (1.22–13.7) 0.022
Note: Reference variables in italics.
ADC, adenocarcinoma; SCC, squamous cell carcinoma; ypCR, pathologic complete response; OR, Odds
Ratio.
https://doi.org/10.1371/journal.pone.0184737.t004
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and low survival in the multivariate Cox Regression analysis, consistent with previous reports
[19,20].
Regardless the improvement of surgical techniques and radiotherapy constraints, half of the
patients with LAEC will relapse, mostly within the first 3 years during the follow up. In our
series, distant recurrence was more prevalent for ADC, whereas SCC tended to relapse loco-
regionally (p-value = 0.032), probably due to a higher potential metastatic risk associated with
ADC.
Surveillance after treatment is performed routinely for both histologic subtypes and
includes image test, and biomarker test with CA 19–9 and CEA, only for adenocarcinomas.
The effort to find potential predictive biomarkers in this setting will help us to identify not
only which patients are at higher risk of relapse, but also to characterize recurrence patterns
which leads to adapt follow up strategies [21].
Differences in OS according to histologic subtype were more favourable to SCC compared
to ADC (45m vs 26m) despite not being statistically significant. Differences in OS and recur-
rence pattern according to histologic subtypes have been previously reported [22–24] but data
are not consistent because no phase III randomized clinical trials have properly addressed this
issue.
Second line strategies
Further therapeutic strategies in case of relapse or refractoriness are scarce and there is no con-
sensus on the optimal second-line regimen because of the lack of efficient therapies. Further-
more, current data on second-line treatment recommendations are based on relatively small
studies in a highly-selected cohort of patients. However, approximately 50% of patients who
relapse are potential candidates to receive second line treatment, mostly those who preserve a
Table 5. Recurrence rate and patterns of recurrence according to histologic subtype.
Recurrence Rate All Patients N = 83 SCC N = 35 ADC N = 45
Recurrence Rate—n (%)
Overall 36–43% 12–34% 21–47%
1st year 30–36% 9–26% 18–40%
3rd year 36–43% 12–34% 21–47%
Site of recurrence N = 33 (100%) SCC N = 12 ADCN = 21 P-value
Locorregional (LR)—n (%) 8 (24%) 6 (75%) 2(25%) 0.027
Distant (D)—n (%) 18 (55%) 5 (28%) 13 (72%)
Synchronic LR+D—n (%) 7 (21%) 1 (14%) 6 (86%)
https://doi.org/10.1371/journal.pone.0184737.t005
Table 6. Treatment at recurrence.
Treatment at first recurrence N = 18 (100%)
Radiotherapy—n (%) 1 (6)
Chemo-RT—n (%) 1 (6)
Salvage surgery—n (%) 1 (6)
Palliative chemotherapy—n (%) 15 (83)
Docetaxel 7 (47)
Cisplatin plus 5-fluoracyl 3 (20)
Carboplatin plus 5-fluoracyl 2 (13)
Others 1 (7)
Unknown 2 (13)
https://doi.org/10.1371/journal.pone.0184737.t006
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good performance status [25]. Local therapies such as RT or surgery represent efficient options
that offer more aggressive approach when disease progresses in a single metastatic site. In our
series, we observed 11% of oligoprogressions among patients who relapsed. Despite its low
prevalence, there is a growing interest in many cancer types due to its potential benefit in OS
when curative-intention options can be offered [26]. Larger cohorts of patients addressing this
issue should be developed in order to stablish more conclusive statements.
Identifying biomarkers
Esophageal carcinoma represents a heterogeneous disease with different outcomes and
response grade to conventional therapies. The attempt to establish molecular subtypes based
on genetic and molecular alterations tries to find potential predictive and prognostic biomark-
ers in order to investigate the role of tailored therapies to improve the current treatment.
[27–29].
Amplification of ERBB2, which encodes for the HER2 protein is present almost in 7 to 34%
of esophagogastric ADC. The TOGA phase III trial, demonstrated improvement in OS with
the addition of Trastuzumab to conventional first line chemotherapy in patients with meta-
static/recurrent HER2–expressing gastric and EGJ cancer [30]. This was the first study to
incorporate a biologic agent into the treatment of upper gastrointestinal cancer. Its implica-
tions for locally advanced disease are currently being investigated in the Radiation Therapy
Oncology Group 1010 trial (NCT01196390), which incorporates trastuzumab with a CROSS-
like regimen for HER2-overexpressing esophageal ADC.
Two large-scale studies from the ICGC (International Cancer Genome Consortium) and
TCGA (The Cancer Genome Atlas) have been recently published with the aim to better char-
acterize esophageal cancer at the molecular level [31, 32]. They demonstrate that cancers that
develop in the same location can vary greatly at this level. The mutational profile of esophageal
SCC closely resembles that of squamous cell carcinomas from other tissues, and the genomic
alterations profile of esophageal ADC is closely similar to the CIN (chromosomal instability)
variant of gastric cancer.
Conclusions
Despite recent improvements in staging techniques and supportive management of LAEC its
prognosis is still poor, mostly due to early recurrences. The optimal management of these
patients should involve a multidisciplinary team of healthcare professionals in order to
improve therapeutic results.
Because ADC and SCC have distinct predisposing risk factors and clinic-pathologic charac-
teristics, histology-specific assessment is relevant in terms of prevention and therapeutic man-
agement. The different outcomes evidenced in our retrospective cohort between the two main
histologic subtypes has not been directly assessed in randomized clinical trials but the differ-
ences observed might lead to improve the follow-up approach in this setting. In addition, an
optimal molecular characterization might help us to better understand pathogenesis of the dis-
ease and will contribute to develop further therapeutic strategies. Efforts to validate new pre-
dictive biomarkers, together with the histopathological subtype, would help to identify which
patients are at higher risk of relapse in our current clinical practise, in order to offer them
rationally designed follow up and therapeutic strategies.
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